메뉴 건너뛰기




Volumn 59, Issue 9, 2019, Pages 3002-3025

Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)

(21)  Atreya, Chintamani a   Glynn, Simone b   Busch, Michael c   Kleinman, Steve d   Snyder, Edward d   Rutter, Sara e   AuBuchon, James f   Flegel, Willy g   Reeve, David h   Devine, Dana i   Cohn, Claudia i   Custer, Brian c   Goodrich, Raymond j   Benjamin, Richard J k   Razatos, Anna l   Cancelas, Jose m   Wagner, Stephen h   Maclean, Michelle n   Gelderman, Monique a   Cap, Andrew o   more..


Author keywords

[No Author keywords available]

Indexed keywords

BLOOD COMPONENT; BLOOD DONOR; BLOOD SAFETY; BLOOD TRANSFUSION; BLOODSTREAM INFECTION; CONFERENCE PAPER; DISEASE TRANSMISSION; ERYTHROCYTE; FOOD AND DRUG ADMINISTRATION; GRAFT VERSUS HOST REACTION; HEALTH ECONOMICS; HUMAN; INFECTION RISK; NONHUMAN; PLATELET COUNT; REPRODUCIBILITY; RISK ASSESSMENT; UNITED STATES; BLOOD TRANSFUSION REACTION; BLOODBORNE BACTERIUM; DISINFECTION; HISTORY; ISOLATION AND PURIFICATION; MICROBIAL VIABILITY; MICROBIOLOGY; ORGANIZATION; ORGANIZATION AND MANAGEMENT; PANDEMIC; PARASITOLOGY; PREVENTION AND CONTROL; PROCEDURES; VIROLOGY;

EID: 85066835721     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.15344     Document Type: Conference Paper
Times cited : (28)

References (187)
  • 1
    • 78649487218 scopus 로고    scopus 로고
    • Transfusion-associated infections: 50 years of relentless challenges and remarkable progress
    • Perkins HA, Busch MP. Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion 2010;50:2080-99.
    • (2010) Transfusion , vol.50 , pp. 2080-2099
    • Perkins, H.A.1    Busch, M.P.2
  • 2
    • 4143071570 scopus 로고    scopus 로고
    • Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing
    • Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004;351:760-8.
    • (2004) N Engl J Med , vol.351 , pp. 760-768
    • Stramer, S.L.1    Glynn, S.A.2    Kleinman, S.H.3
  • 3
    • 70449085441 scopus 로고    scopus 로고
    • Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion
    • Kleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009;49:2454-89.
    • (2009) Transfusion , vol.49 , pp. 2454-2489
    • Kleinman, S.H.1    Lelie, N.2    Busch, M.P.3
  • 4
    • 85065299876 scopus 로고    scopus 로고
    • Prevention of transfusion transmitted infections
    • Busch MP, Bloch EM, Kleinman SH. Prevention of transfusion transmitted infections. Blood. 2019;133(17):1854-64.
    • (2019) Blood , vol.133 , Issue.17 , pp. 1854-1864
    • Busch, M.P.1    Bloch, E.M.2    Kleinman, S.H.3
  • 5
    • 68149125565 scopus 로고    scopus 로고
    • Emerging infectious disease agents and their potential threat to transfusion safety
    • Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009;49(Suppl 2):1S-29S.
    • (2009) Transfusion , vol.49 , pp. 1S-29S
    • Stramer, S.L.1    Hollinger, F.B.2    Katz, L.M.3
  • 6
    • 84873420262 scopus 로고    scopus 로고
    • Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century
    • Glynn SA, Busch MP, Dodd RY, et al. Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century. Transfusion 2013;53:438-54.
    • (2013) Transfusion , vol.53 , pp. 438-454
    • Glynn, S.A.1    Busch, M.P.2    Dodd, R.Y.3
  • 7
    • 80051612913 scopus 로고    scopus 로고
    • FDA workshop on emerging infectious diseases: evaluating emerging infectious diseases (EIDs) for transfusion safety
    • Atreya C, Nakhasi H, Mied P, et al. FDA workshop on emerging infectious diseases: evaluating emerging infectious diseases (EIDs) for transfusion safety. Transfusion 2011;51:1855-71.
    • (2011) Transfusion , vol.51 , pp. 1855-1871
    • Atreya, C.1    Nakhasi, H.2    Mied, P.3
  • 8
    • 85059096850 scopus 로고    scopus 로고
    • Impact of one-time testing for Trypanosoma cruzi antibodies among blood donors in the United States
    • Dodd R, Groves JA, Townsend RL, et al. Impact of one-time testing for Trypanosoma cruzi antibodies among blood donors in the United States. Transfusion 2019;59:1016-23.
    • (2019) Transfusion , vol.59 , pp. 1016-1023
    • Dodd, R.1    Groves, J.A.2    Townsend, R.L.3
  • 9
    • 23044469979 scopus 로고    scopus 로고
    • Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing
    • Busch MP, Caglioti S, Robertson EF, et al. Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med 2005;353:460-7.
    • (2005) N Engl J Med , vol.353 , pp. 460-467
    • Busch, M.P.1    Caglioti, S.2    Robertson, E.F.3
  • 10
    • 84930570786 scopus 로고    scopus 로고
    • Keeping blood transfusion safe from West Nile virus: American Red Cross Experience, 2003 to 2012
    • Dodd RY, Foster GA, Stramer SL. Keeping blood transfusion safe from West Nile virus: American Red Cross Experience, 2003 to 2012. Transfus Med Rev 2015;29:153-61.
    • (2015) Transfus Med Rev , vol.29 , pp. 153-161
    • Dodd, R.Y.1    Foster, G.A.2    Stramer, S.L.3
  • 11
    • 85013676204 scopus 로고    scopus 로고
    • First cases of Zika virus-infected US blood donors outside states with areas of active transmission
    • Williamson PC, Linnen JM, Kessler DA, et al. First cases of Zika virus-infected US blood donors outside states with areas of active transmission. Transfusion 2017;57(3pt2):770-8.
    • (2017) Transfusion , vol.57 , Issue.3pt2 , pp. 770-778
    • Williamson, P.C.1    Linnen, J.M.2    Kessler, D.A.3
  • 12
    • 85046961659 scopus 로고    scopus 로고
    • Investigational testing for Zika Virus among U.S. blood donors
    • Saa P, Proctor M, Foster G, et al. Investigational testing for Zika Virus among U.S. blood donors. N Engl J Med 2018;378:1778-88.
    • (2018) N Engl J Med , vol.378 , pp. 1778-1788
    • Saa, P.1    Proctor, M.2    Foster, G.3
  • 13
    • 85003748575 scopus 로고    scopus 로고
    • Screening for Babesia microti in the U.S. Blood Supply
    • Moritz ED, Winton CS, Tonnetti L, et al. Screening for Babesia microti in the U.S. Blood Supply. N Engl J Med 2016;375:2236-45.
    • (2016) N Engl J Med , vol.375 , pp. 2236-2245
    • Moritz, E.D.1    Winton, C.S.2    Tonnetti, L.3
  • 14
    • 85053034044 scopus 로고    scopus 로고
    • Assessing the risk of Babesia to the United States blood supply using a risk-based decision-making approach: Report of AABB's Ad Hoc Babesia Policy Working Group (original report)
    • Ward SJ, Stramer SL, Szczepiorkowski ZM. Assessing the risk of Babesia to the United States blood supply using a risk-based decision-making approach: Report of AABB's Ad Hoc Babesia Policy Working Group (original report). Transfusion 2018;58:1916-23.
    • (2018) Transfusion , vol.58 , pp. 1916-1923
    • Ward, S.J.1    Stramer, S.L.2    Szczepiorkowski, Z.M.3
  • 15
    • 85021339267 scopus 로고    scopus 로고
    • Residual risk of bacterial contamination of platelets: six years of experience with sterility testing
    • Ramirez-Arcos S, DiFranco C, McIntyre T, et al. Residual risk of bacterial contamination of platelets: six years of experience with sterility testing. Transfusion 2017;57:2174-81.
    • (2017) Transfusion , vol.57 , pp. 2174-2181
    • Ramirez-Arcos, S.1    DiFranco, C.2    McIntyre, T.3
  • 16
    • 84952685517 scopus 로고    scopus 로고
    • Creutzfeldt-Jakob disease and blood transfusion: updated results of the UK Transfusion Medicine Epidemiology Review Study
    • Urwin PJ, Mackenzie JM, Llewelyn CA, et al. Creutzfeldt-Jakob disease and blood transfusion: updated results of the UK Transfusion Medicine Epidemiology Review Study. Vox Sang 2016;110:310-6.
    • (2016) Vox Sang , vol.110 , pp. 310-316
    • Urwin, P.J.1    Mackenzie, J.M.2    Llewelyn, C.A.3
  • 17
    • 70350488874 scopus 로고    scopus 로고
    • Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome
    • Lombardi VC, Ruscetti FW, Das Gupta J, et al. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009;326:585-9.
    • (2009) Science , vol.326 , pp. 585-589
    • Lombardi, V.C.1    Ruscetti, F.W.2    Das Gupta, J.3
  • 18
    • 81055140369 scopus 로고    scopus 로고
    • Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study
    • Simmons G, Glynn SA, Komaroff AL, et al. Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science 2011;334:814-7.
    • (2011) Science , vol.334 , pp. 814-817
    • Simmons, G.1    Glynn, S.A.2    Komaroff, A.L.3
  • 19
    • 85053510347 scopus 로고    scopus 로고
    • Risk-based decision-making in transfusion medicine
    • Bennett JL, Devine DV. Risk-based decision-making in transfusion medicine. Vox Sang 2018;113:737-49.
    • (2018) Vox Sang , vol.113 , pp. 737-749
    • Bennett, J.L.1    Devine, D.V.2
  • 20
    • 85046966482 scopus 로고    scopus 로고
    • Revisiting blood safety practices given emerging data about Zika virus
    • Bloch EM, Ness PM, Tobian AAR, et al. Revisiting blood safety practices given emerging data about Zika virus. N Engl J Med 2018;378:1837-41.
    • (2018) N Engl J Med , vol.378 , pp. 1837-1841
    • Bloch, E.M.1    Ness, P.M.2    Tobian, A.A.R.3
  • 25
    • 84957539268 scopus 로고    scopus 로고
    • Chemical and biological mechanisms of pathogen reduction technologies
    • Mundt J, Rouse L, Van den Bossche J, et al. Chemical and biological mechanisms of pathogen reduction technologies. Photochem Photobiol 2014;90:957-64.
    • (2014) Photochem Photobiol , vol.90 , pp. 957-964
    • Mundt, J.1    Rouse, L.2    Van den Bossche, J.3
  • 26
    • 84906559343 scopus 로고    scopus 로고
    • Pathogen inactivation technologies for cellular blood components: an update
    • Schlenke P. Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother 2014;41:309-25.
    • (2014) Transfus Med Hemother , vol.41 , pp. 309-325
    • Schlenke, P.1
  • 27
    • 85061835969 scopus 로고    scopus 로고
    • Pathogen inactivation of cellular blood products- an additional safety layer in transfusion medicine
    • Seltam A. Pathogen inactivation of cellular blood products- an additional safety layer in transfusion medicine. Front Med (Lausanne) 2017;4:219.
    • (2017) Front Med (Lausanne) , vol.4 , pp. 219
    • Seltam, A.1
  • 28
    • 85066831902 scopus 로고    scopus 로고
    • Terumo BCT announces enrollment of the first patient in its U.S. clinical trial designed to study platelets treated with the Mirasol® pathogen reduction technology (PRT) system [Internet]. Lakewood (CO) Terumo BCT; 2017. Available from
    • Terumo BCT. Terumo BCT announces enrollment of the first patient in its U.S. clinical trial designed to study platelets treated with the Mirasol® pathogen reduction technology (PRT) system [Internet]. Lakewood (CO): Terumo BCT; 2017. Available from: https://www.terumobct.com/Pages/News/Press%20Releases/Terumo-BCT-Announces-Enrollment-of-the-First-Patient--in-Its-U-S--Clinical-Trial-Designed-to-Study-Platelets-Treated--With-.aspx.
    • Terumo, B.C.T.1
  • 29
    • 84931567550 scopus 로고    scopus 로고
    • Tolerance of platelet concentrates treated with UVC-light only for pathogen reduction- a phase I clinical trial
    • Thiele T, Pohler P, Kohlmann T, et al. Tolerance of platelet concentrates treated with UVC-light only for pathogen reduction- a phase I clinical trial. Vox Sang 2015;109:44-51.
    • (2015) Vox Sang , vol.109 , pp. 44-51
    • Thiele, T.1    Pohler, P.2    Kohlmann, T.3
  • 30
    • 85053197550 scopus 로고    scopus 로고
    • Pathogen-inactivated blood products for pediatric patients: blood safety, patient safety, or both?
    • Jaquot C, Delaney M. Pathogen-inactivated blood products for pediatric patients: blood safety, patient safety, or both? Transfusion 2018;58:2095-101.
    • (2018) Transfusion , vol.58 , pp. 2095-2101
    • Jaquot, C.1    Delaney, M.2
  • 31
    • 85007360645 scopus 로고    scopus 로고
    • Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian regional medical center
    • Amato M, Schennach H, Astl M, et al. Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian regional medical center. Vox Sang 2017;112:47-55.
    • (2017) Vox Sang , vol.112 , pp. 47-55
    • Amato, M.1    Schennach, H.2    Astl, M.3
  • 32
    • 85013170768 scopus 로고    scopus 로고
    • Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients
    • Nussbaumer W, Amato M, Schennach H, et al. Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients. Vox Sang 2017;112:249-56.
    • (2017) Vox Sang , vol.112 , pp. 249-256
    • Nussbaumer, W.1    Amato, M.2    Schennach, H.3
  • 33
    • 84944271950 scopus 로고    scopus 로고
    • A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Swissmedic Haemovigilance Annual Report 2014
    • Knutson F, Osselaer J, Pierelli L, et al. A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Swissmedic Haemovigilance Annual Report 2014. Vox Sang 2015;109:343-52.
    • (2015) Vox Sang , vol.109 , pp. 343-352
    • Knutson, F.1    Osselaer, J.2    Pierelli, L.3
  • 34
    • 85065128334 scopus 로고    scopus 로고
    • Transfusion reaction rates of pathogen reduced (PR) vs conventional (CONV) platelets in adults: a single academic center experience
    • Gokhale A, Schulz W, Bahar B, et al. Transfusion reaction rates of pathogen reduced (PR) vs conventional (CONV) platelets in adults: a single academic center experience. Transfusion 2018;58(S2). https://onlinelibrary.wiley.com/doi/10.1111/trf.14903):6A-254A.
    • (2018) Transfusion , vol.58 , Issue.S2 , pp. 6A-254A
    • Gokhale, A.1    Schulz, W.2    Bahar, B.3
  • 35
    • 85065128334 scopus 로고    scopus 로고
    • A retrospective evaluation of the hemostatic efficacy of pathogen reduced (PR) vs conventional (CONV) platelets at an academic medical center
    • Gehrie E, Schulz W, Young P, et al. A retrospective evaluation of the hemostatic efficacy of pathogen reduced (PR) vs conventional (CONV) platelets at an academic medical center. Transfusion 2018;58(S2). https://onlinelibrary.wiley.com/doi/10.1111/trf.14903):6A-254A.
    • (2018) Transfusion , vol.58 , Issue.S2 , pp. 6A-254A
    • Gehrie, E.1    Schulz, W.2    Young, P.3
  • 36
    • 85065128334 scopus 로고    scopus 로고
    • Transfusion of pathogen reduced (PR) vs conventional (CONV) platelets in pediatric patients: an assessment of platelet usage and incidence of transfusion reactions
    • Schulz W, Gokhale A, McPadden J, et al. Transfusion of pathogen reduced (PR) vs conventional (CONV) platelets in pediatric patients: an assessment of platelet usage and incidence of transfusion reactions. Transfusion 2018;58(S2). https://onlinelibrary.wiley.com/doi/10.1111/trf.14903):6A-254A.
    • (2018) Transfusion , vol.58 , Issue.S2 , pp. 6A-254A
    • Schulz, W.1    Gokhale, A.2    McPadden, J.3
  • 37
    • 84943818347 scopus 로고    scopus 로고
    • Cost implications of implementation of pathogen-inactivated platelets
    • McCullough J, Goldfinger D, Gorlin J, et al. Cost implications of implementation of pathogen-inactivated platelets. Transfusion 2015;55:2312-20.
    • (2015) Transfusion , vol.55 , pp. 2312-2320
    • McCullough, J.1    Goldfinger, D.2    Gorlin, J.3
  • 38
    • 85050982980 scopus 로고    scopus 로고
    • Economic implications of pathogen reduced and bacterially tested platelet components: a US hospital budget impact model
    • Prioli K, Katz J, Lyons N, et al. Economic implications of pathogen reduced and bacterially tested platelet components: a US hospital budget impact model. Appl Health Econ Health Policy 2018;16:889-99.
    • (2018) Appl Health Econ Health Policy , vol.16 , pp. 889-899
    • Prioli, K.1    Katz, J.2    Lyons, N.3
  • 39
    • 23844453081 scopus 로고    scopus 로고
    • Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital factor deficiencies
    • de Alarcon P, Benjamin R, Dugdale M, et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital factor deficiencies. Transfusion 2005;45:1362-72.
    • (2005) Transfusion , vol.45 , pp. 1362-1372
    • de Alarcon, P.1    Benjamin, R.2    Dugdale, M.3
  • 40
    • 85066872574 scopus 로고    scopus 로고
    • Quantitative analysis of plasma proteins in whole-blood derived fresh frozen plasma prepare with three pathogen reduction technologies
    • Larrea L, Ortiz-de-Salazar M-I, Martinez P, et al. Quantitative analysis of plasma proteins in whole-blood derived fresh frozen plasma prepare with three pathogen reduction technologies. Transfus Apher Sci 2009;41:199-204.
    • (2009) Transfus Apher Sci , vol.41 , pp. 199-204
    • Larrea, L.1    Ortiz-de-Salazar, M.-I.2    Martinez, P.3
  • 41
    • 77950239200 scopus 로고    scopus 로고
    • Protein quality in Mirasol pathogen reduction technology-treated apheresis-derived fresh-frozen plasma
    • Smith J, Rock G. Protein quality in Mirasol pathogen reduction technology-treated apheresis-derived fresh-frozen plasma. Transfusion 2010;50:926-31.
    • (2010) Transfusion , vol.50 , pp. 926-931
    • Smith, J.1    Rock, G.2
  • 42
    • 84900483776 scopus 로고    scopus 로고
    • Paired analysis of plasma proteins and coagulation capacity after treatment with three methods of pathogen reduction
    • Coene J, Devreese K, Sabot B, et al. Paired analysis of plasma proteins and coagulation capacity after treatment with three methods of pathogen reduction. Transfusion 2014;54:1321-31.
    • (2014) Transfusion , vol.54 , pp. 1321-1331
    • Coene, J.1    Devreese, K.2    Sabot, B.3
  • 43
    • 70350462130 scopus 로고    scopus 로고
    • Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulation proteins
    • Hornsy VS, Drummond O, Morrison A, et al. Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulation proteins. Transfusion 2009;49:2167-72.
    • (2009) Transfusion , vol.49 , pp. 2167-2172
    • Hornsy, V.S.1    Drummond, O.2    Morrison, A.3
  • 44
    • 85005900899 scopus 로고    scopus 로고
    • Quarantine versus pathogen-reduced plasma-coagulation factor content and rotational thromboelastometry coagulation
    • Theusinger OM, Goslings D, Studt J-D, et al. Quarantine versus pathogen-reduced plasma-coagulation factor content and rotational thromboelastometry coagulation. Transfusion 2017;57:637-45.
    • (2017) Transfusion , vol.57 , pp. 637-645
    • Theusinger, O.M.1    Goslings, D.2    Studt, J.-D.3
  • 45
    • 73649129231 scopus 로고    scopus 로고
    • Intercept plasma: comparability with conventional fresh-frozen plasma based on coagulation function - an in vitro analysis
    • Irsch J, Pinkosky L, Corash L, et al. Intercept plasma: comparability with conventional fresh-frozen plasma based on coagulation function - an in vitro analysis. Vox Sang 2010;98:47-55.
    • (2010) Vox Sang , vol.98 , pp. 47-55
    • Irsch, J.1    Pinkosky, L.2    Corash, L.3
  • 46
    • 55149111374 scopus 로고    scopus 로고
    • Indications for use and cost-effectiveness of pathogen-reduced ABO-universal plasma
    • Solheim BG, Chetty R, Flesland O. Indications for use and cost-effectiveness of pathogen-reduced ABO-universal plasma. Curr Opin Hematol 2008;15:612-7.
    • (2008) Curr Opin Hematol , vol.15 , pp. 612-617
    • Solheim, B.G.1    Chetty, R.2    Flesland, O.3
  • 47
    • 84874949948 scopus 로고    scopus 로고
    • Quantitative and qualitative analysis of coagulation factors in cryoprecipitate prepared from fresh-frozen plasma inactivated with amotosalen and ultraviolet A light
    • Cid J, Caballo C, Pino M, et al. Quantitative and qualitative analysis of coagulation factors in cryoprecipitate prepared from fresh-frozen plasma inactivated with amotosalen and ultraviolet A light. Transfusion 2013;53:600-5.
    • (2013) Transfusion , vol.53 , pp. 600-605
    • Cid, J.1    Caballo, C.2    Pino, M.3
  • 48
    • 84858285463 scopus 로고    scopus 로고
    • Preparation of cryoprecipitate from riboflavin and UV-light treated plasma
    • Ettinger A, Miklauz MM, Bihm DJ, et al. Preparation of cryoprecipitate from riboflavin and UV-light treated plasma. Transfus Apher Sci 2012;46:153-8.
    • (2012) Transfus Apher Sci , vol.46 , pp. 153-158
    • Ettinger, A.1    Miklauz, M.M.2    Bihm, D.J.3
  • 49
    • 84954401850 scopus 로고    scopus 로고
    • Effect of riboflavin and amotosalen photoactivation systems for pathogen inactivation of fresh-frozen plasma on fibrin clot structure
    • Hubbard T, Backholer L, Wiltshire M, et al. Effect of riboflavin and amotosalen photoactivation systems for pathogen inactivation of fresh-frozen plasma on fibrin clot structure. Transfusion 2016;56:41-8.
    • (2016) Transfusion , vol.56 , pp. 41-48
    • Hubbard, T.1    Backholer, L.2    Wiltshire, M.3
  • 50
    • 84937022864 scopus 로고    scopus 로고
    • Comparative effectiveness of plasma prepared with amotosalen-UVA pathogen inactivation and conventional plasma for support of liver transplantation
    • Cinqualbre J, Kientz D, Remy E, et al. Comparative effectiveness of plasma prepared with amotosalen-UVA pathogen inactivation and conventional plasma for support of liver transplantation. Transfusion 2015;55:1710-20.
    • (2015) Transfusion , vol.55 , pp. 1710-1720
    • Cinqualbre, J.1    Kientz, D.2    Remy, E.3
  • 51
    • 33748950122 scopus 로고    scopus 로고
    • A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura
    • Mintz PD, Neff A, MacKenzie M, et al. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006;46:1693-704.
    • (2006) Transfusion , vol.46 , pp. 1693-1704
    • Mintz, P.D.1    Neff, A.2    MacKenzie, M.3
  • 52
    • 85034993425 scopus 로고    scopus 로고
    • Amotosalen-inactivated plasma is equally well tolerated as quarantine plasma in patients undergoing large volume therapeutic plasma exchange
    • Guignier C, Benamara A, Oriol P, et al. Amotosalen-inactivated plasma is equally well tolerated as quarantine plasma in patients undergoing large volume therapeutic plasma exchange. Transfus Clin Biol 2018;25:73-7.
    • (2018) Transfus Clin Biol , vol.25 , pp. 73-77
    • Guignier, C.1    Benamara, A.2    Oriol, P.3
  • 53
    • 84908226307 scopus 로고    scopus 로고
    • Low incidence of hyperfibrinolysis and thromboembolism in 195 primary liver transplantations transfused with solvent/detergent-treated plasma
    • Haugaa H, Taraldsrud E, Nyrerød HC, et al. Low incidence of hyperfibrinolysis and thromboembolism in 195 primary liver transplantations transfused with solvent/detergent-treated plasma. Clin Med Res 2014;12:27-32.
    • (2014) Clin Med Res , vol.12 , pp. 27-32
    • Haugaa, H.1    Taraldsrud, E.2    Nyrerød, H.C.3
  • 54
    • 0037600705 scopus 로고    scopus 로고
    • Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura
    • Yarranton H, Cohen H, Pavord SR, et al. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 2003;121:778-85.
    • (2003) Br J Haematol , vol.121 , pp. 778-785
    • Yarranton, H.1    Cohen, H.2    Pavord, S.R.3
  • 55
    • 84966668103 scopus 로고    scopus 로고
    • Will pathogen reduction of blood components harm more people than it helps in developed countries
    • Hess JR, Pagano MB, Barbeau JD, et al. Will pathogen reduction of blood components harm more people than it helps in developed countries. Transfusion 2016;56:1236-41.
    • (2016) Transfusion , vol.56 , pp. 1236-1241
    • Hess, J.R.1    Pagano, M.B.2    Barbeau, J.D.3
  • 56
    • 85013807573 scopus 로고    scopus 로고
    • Pathogen inactivation treatment of plasma and platelet concentrates and their predicted functionality in massive transfusion protocols
    • Arbaeen AF, Schubert P, Serrano K, et al. Pathogen inactivation treatment of plasma and platelet concentrates and their predicted functionality in massive transfusion protocols. Transfusion 2017;57:1208-17.
    • (2017) Transfusion , vol.57 , pp. 1208-1217
    • Arbaeen, A.F.1    Schubert, P.2    Serrano, K.3
  • 57
    • 85026761733 scopus 로고    scopus 로고
    • Comparing transfusion reaction rates for various plasma types: a systematic review and meta-analysis/regression
    • Saadah NH, van Hout FMA, Schipperus NR, et al. Comparing transfusion reaction rates for various plasma types: a systematic review and meta-analysis/regression. Transfusion 2017;57:2104-14.
    • (2017) Transfusion , vol.57 , pp. 2104-2114
    • Saadah, N.H.1    van Hout, F.M.A.2    Schipperus, N.R.3
  • 58
    • 33748475913 scopus 로고    scopus 로고
    • Update on pathogen reduction technology for therapeutic plasma: an overview
    • Solheim BG, Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transf Apher Sci 2006;35:83-90.
    • (2006) Transf Apher Sci , vol.35 , pp. 83-90
    • Solheim, B.G.1    Seghatchian, J.2
  • 59
    • 79851482225 scopus 로고    scopus 로고
    • The use of solvent/detergent treatment in pathogen reduction of plamsa
    • Hellstern P, Solheim BG. The use of solvent/detergent treatment in pathogen reduction of plamsa. Transf Med Hemother 2011;38:65-70.
    • (2011) Transf Med Hemother , vol.38 , pp. 65-70
    • Hellstern, P.1    Solheim, B.G.2
  • 60
    • 0041639518 scopus 로고    scopus 로고
    • Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma
    • Riedler GF, Haycox AR, Duggan AK, et al. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang 2003;85:88-95.
    • (2003) Vox Sang , vol.85 , pp. 88-95
    • Riedler, G.F.1    Haycox, A.R.2    Duggan, A.K.3
  • 61
    • 84942949484 scopus 로고
    • Safety and cost-effectiveness of solvent-detergent treated plasma. In search of a zero-risk blood supply
    • AuBuchon JP, Birkmeyer JD. Safety and cost-effectiveness of solvent-detergent treated plasma. In search of a zero-risk blood supply. JAMA 1994;272:1210-4.
    • (1994) JAMA , vol.272 , pp. 1210-1214
    • AuBuchon, J.P.1    Birkmeyer, J.D.2
  • 62
    • 84891702001 scopus 로고    scopus 로고
    • Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress
    • Stramer SL, Dodd RY. Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress. Transfusion 2013;53:2375-83.
    • (2013) Transfusion , vol.53 , pp. 2375-2383
    • Stramer, S.L.1    Dodd, R.Y.2
  • 63
    • 80053969260 scopus 로고    scopus 로고
    • The NIH Clinical Center and the future of clinical research
    • Gallin JI. The NIH Clinical Center and the future of clinical research. Nat Med 2011;17:1221-3.
    • (2011) Nat Med , vol.17 , pp. 1221-1223
    • Gallin, J.I.1
  • 64
    • 85047452388 scopus 로고    scopus 로고
    • Pathogen inactivation strategies to improve blood safety: let's not throw pathogen-reduced platelets out with their bath water
    • Devine DV. Pathogen inactivation strategies to improve blood safety: let's not throw pathogen-reduced platelets out with their bath water. JAMA Oncol 2018;4:458-9.
    • (2018) JAMA Oncol , vol.4 , pp. 458-459
    • Devine, D.V.1
  • 65
    • 84859748210 scopus 로고    scopus 로고
    • Spray: single-donor plasma product for room temperature storage
    • Booth GS, Lozier JN, Nghiem K, et al. Spray: single-donor plasma product for room temperature storage. Transfusion 2012;52:828-33.
    • (2012) Transfusion , vol.52 , pp. 828-833
    • Booth, G.S.1    Lozier, J.N.2    Nghiem, K.3
  • 66
    • 0026543642 scopus 로고
    • Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma
    • Horowitz B, Bonomo R, Prince AM, et al. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992;79:826-31.
    • (1992) Blood , vol.79 , pp. 826-831
    • Horowitz, B.1    Bonomo, R.2    Prince, A.M.3
  • 67
    • 78349253751 scopus 로고    scopus 로고
    • The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model
    • Custer B, Agapova M, Martinez RH. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 2010;50:2461-73.
    • (2010) Transfusion , vol.50 , pp. 2461-2473
    • Custer, B.1    Agapova, M.2    Martinez, R.H.3
  • 68
    • 85052675565 scopus 로고    scopus 로고
    • Addressing gaps in international blood availability and transfusion safety in low- and middle-income countries: a NHLBI workshop
    • Custer B, Zou S, Glynn SA, et al. Addressing gaps in international blood availability and transfusion safety in low- and middle-income countries: a NHLBI workshop. Transfusion 2018;58:1307-17.
    • (2018) Transfusion , vol.58 , pp. 1307-1317
    • Custer, B.1    Zou, S.2    Glynn, S.A.3
  • 69
    • 85047415487 scopus 로고    scopus 로고
    • Nationwide implementation of pathogen inactivation for all platelet concentrates in Switzerland
    • Jutzi M, Mansouri Taleghani B, Rueesch M, et al. Nationwide implementation of pathogen inactivation for all platelet concentrates in Switzerland. Transfus Med Hemother 2018;45:151-6.
    • (2018) Transfus Med Hemother , vol.45 , pp. 151-156
    • Jutzi, M.1    Mansouri Taleghani, B.2    Rueesch, M.3
  • 70
    • 0027980227 scopus 로고
    • Cellular gene therapy: an overview
    • Klein HG. Cellular gene therapy: an overview. J Clin Apher 1994;9:139-41.
    • (1994) J Clin Apher , vol.9 , pp. 139-141
    • Klein, H.G.1
  • 71
    • 0023918549 scopus 로고
    • Technical aspects of lymphokine-activated killer cell production
    • Carter CS, Leitman SF, Cullis H, et al. Technical aspects of lymphokine-activated killer cell production. J Clin Apher 1988;4:113-7.
    • (1988) J Clin Apher , vol.4 , pp. 113-117
    • Carter, C.S.1    Leitman, S.F.2    Cullis, H.3
  • 72
    • 0028318470 scopus 로고
    • Immunologic aspects of blood transfusion
    • Klein HG. Immunologic aspects of blood transfusion. Semin Oncol 1994;21:16-20.
    • (1994) Semin Oncol , vol.21 , pp. 16-20
    • Klein, H.G.1
  • 73
    • 0034109924 scopus 로고    scopus 로고
    • Leukocyte depletion of red cell components prevents exposure of transfusion recipients to neutrophil elastase
    • Willy C, Reithmeier W, Kuhlmann WD, et al. Leukocyte depletion of red cell components prevents exposure of transfusion recipients to neutrophil elastase. Vox Sang 2000;78:19-27.
    • (2000) Vox Sang , vol.78 , pp. 19-27
    • Willy, C.1    Reithmeier, W.2    Kuhlmann, W.D.3
  • 74
    • 85066841062 scopus 로고    scopus 로고
    • Transfusion of fresh vs. older red blood cells in the context of infection
    • Klein H, Natanson C, Flegel W. Transfusion of fresh vs. older red blood cells in the context of infection. ISBT Sci Ser 2015;10:275-85.
    • (2015) ISBT Sci Ser , vol.10 , pp. 275-285
    • Klein, H.1    Natanson, C.2    Flegel, W.3
  • 75
    • 84896049579 scopus 로고    scopus 로고
    • Does prolonged storage of red blood cells cause harm?
    • Flegel WA, Natanson C, Klein HG. Does prolonged storage of red blood cells cause harm? Br J Haematol 2014;165:3-16.
    • (2014) Br J Haematol , vol.165 , pp. 3-16
    • Flegel, W.A.1    Natanson, C.2    Klein, H.G.3
  • 76
    • 84924571547 scopus 로고    scopus 로고
    • Pathogen inactivation or pathogen reduction: proposal for standardization of nomenclature
    • Lozano M, Cid J, Prowse C, et al. Pathogen inactivation or pathogen reduction: proposal for standardization of nomenclature. Transfusion 2015;55:690.
    • (2015) Transfusion , vol.55 , pp. 690
    • Lozano, M.1    Cid, J.2    Prowse, C.3
  • 77
    • 0034641197 scopus 로고    scopus 로고
    • Will blood transfusion ever be safe enough?
    • Klein HG. Will blood transfusion ever be safe enough? JAMA 2000;284:238-40.
    • (2000) JAMA , vol.284 , pp. 238-240
    • Klein, H.G.1
  • 78
    • 66549119064 scopus 로고    scopus 로고
    • Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop
    • Klein HG, Glynn SA, Ness PM, et al. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop. Transfusion 2009;49:1262-8.
    • (2009) Transfusion , vol.49 , pp. 1262-1268
    • Klein, H.G.1    Glynn, S.A.2    Ness, P.M.3
  • 79
    • 85066879488 scopus 로고    scopus 로고
    • Changes to the 30th edition of Standards for Blood Banks and Transfusion Services
    • Regan D, Markowitz MA. Changes to the 30th edition of Standards for Blood Banks and Transfusion Services. AABB Association Bulletin 2016;#16-05:1-4.
    • (2016) AABB Association Bulletin , vol.16-5 , pp. 1-4
    • Regan, D.1    Markowitz, M.A.2
  • 80
    • 84929377783 scopus 로고    scopus 로고
    • The safety of the blood supply - time to raise the bar
    • Snyder EL, Stramer SL, Benjamin RJ. The safety of the blood supply - time to raise the bar. N Engl J Med 2015;372:1882-5.
    • (2015) N Engl J Med , vol.372 , pp. 1882-1885
    • Snyder, E.L.1    Stramer, S.L.2    Benjamin, R.J.3
  • 81
    • 85066853147 scopus 로고    scopus 로고
    • Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coat
    • van Rhenen DJ, Vermeij J, Mayaudon V, et al. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coat. Vox Sang 2000;76:209-14.
    • (2000) Vox Sang , vol.76 , pp. 209-214
    • van Rhenen, D.J.1    Vermeij, J.2    Mayaudon, V.3
  • 82
    • 84875579333 scopus 로고    scopus 로고
    • In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system
    • Johnson L, Loh YS, Kwok M, et al. In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system. Transfus Med 2013;23:121-9.
    • (2013) Transfus Med , vol.23 , pp. 121-129
    • Johnson, L.1    Loh, Y.S.2    Kwok, M.3
  • 83
    • 1642394887 scopus 로고    scopus 로고
    • Functional characteristics of buffy coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation
    • Picker SM, Speer R, Gathof BS. Functional characteristics of buffy coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion 2004;44:320-9.
    • (2004) Transfusion , vol.44 , pp. 320-329
    • Picker, S.M.1    Speer, R.2    Gathof, B.S.3
  • 84
    • 84926472995 scopus 로고    scopus 로고
    • Whole blood treated with riboflavin and ultraviolet light: quality assessment of all blood components produced by the buffy coat method
    • Schubert P, Culibrk B, Karwal S, et al. Whole blood treated with riboflavin and ultraviolet light: quality assessment of all blood components produced by the buffy coat method. Transfusion 2015;55:815-23.
    • (2015) Transfusion , vol.55 , pp. 815-823
    • Schubert, P.1    Culibrk, B.2    Karwal, S.3
  • 85
    • 84922783109 scopus 로고    scopus 로고
    • Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function
    • Osman A, Hitzler WE, Meyer CU, et al. Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function. Platelets 2015;26:154-63.
    • (2015) Platelets , vol.26 , pp. 154-163
    • Osman, A.1    Hitzler, W.E.2    Meyer, C.U.3
  • 86
    • 84987660523 scopus 로고    scopus 로고
    • Riboflavin and ultraviolet illumination affects selected platelet mRNA transcript amounts differently
    • Klein-Bosgoed C, Schubert P, Devine DV. Riboflavin and ultraviolet illumination affects selected platelet mRNA transcript amounts differently. Transfusion 2016;56:2286-95.
    • (2016) Transfusion , vol.56 , pp. 2286-2295
    • Klein-Bosgoed, C.1    Schubert, P.2    Devine, D.V.3
  • 87
    • 85073837450 scopus 로고    scopus 로고
    • Increased cytokine release from platelet concentrates following riboflavin/UV light treatment accelerates endothelial cell proliferation and migration
    • Schubert P, Culibrk B, Lautens B, et al. Increased cytokine release from platelet concentrates following riboflavin/UV light treatment accelerates endothelial cell proliferation and migration. Transfusion 2013;53(suppl):S84-040A.
    • (2013) Transfusion , vol.53 , pp. S84-040A
    • Schubert, P.1    Culibrk, B.2    Lautens, B.3
  • 88
    • 0037443546 scopus 로고    scopus 로고
    • Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial
    • van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-33.
    • (2003) Blood , vol.101 , pp. 2426-2433
    • van Rhenen, D.1    Gulliksson, H.2    Cazenave, J.P.3
  • 89
    • 4444380592 scopus 로고    scopus 로고
    • Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial
    • McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004;104:1534-41.
    • (2004) Blood , vol.104 , pp. 1534-1541
    • McCullough, J.1    Vesole, D.H.2    Benjamin, R.J.3
  • 90
    • 85047446533 scopus 로고    scopus 로고
    • Pathogen reduced platelets for the prevention of bleeding in people of any age
    • Estcourt LJ, Malouf R, Murphy MF. Pathogen reduced platelets for the prevention of bleeding in people of any age. JAMA Oncol 2018;4:571-2.
    • (2018) JAMA Oncol , vol.4 , pp. 571-572
    • Estcourt, L.J.1    Malouf, R.2    Murphy, M.F.3
  • 91
    • 85047476557 scopus 로고    scopus 로고
    • Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process (EFFIPAP) Study Group. Comparison of the hemostatic efficacy of pathogen-reduced platelets vs untreated platelets in patients with thrombocytopenia and malignant hematologic diseases: a randomized clinical trial
    • Garban F, Guyard A, Labussière H, et al. Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process (EFFIPAP) Study Group. Comparison of the hemostatic efficacy of pathogen-reduced platelets vs untreated platelets in patients with thrombocytopenia and malignant hematologic diseases: a randomized clinical trial. JAMA Oncol 2018;4:468-75.
    • (2018) JAMA Oncol , vol.4 , pp. 468-475
    • Garban, F.1    Guyard, A.2    Labussière, H.3
  • 92
    • 85048103316 scopus 로고    scopus 로고
    • Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial
    • van der Meer PF, Ypma PF, van Geloven N, et al. Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial. Blood 2018;132:223-31.
    • (2018) Blood , vol.132 , pp. 223-231
    • van der Meer, P.F.1    Ypma, P.F.2    van Geloven, N.3
  • 93
    • 84944271950 scopus 로고    scopus 로고
    • A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment
    • Knutson F, Osselaer J, Pierelli L, et al. A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sang 2015;109:343-52.
    • (2015) Vox Sang , vol.109 , pp. 343-352
    • Knutson, F.1    Osselaer, J.2    Pierelli, L.3
  • 94
    • 84929069313 scopus 로고    scopus 로고
    • Solvent/detergent-treated plasma: a tale of 30 years of experience
    • Liumbruno GM, Marano G, Grazzini G, et al. Solvent/detergent-treated plasma: a tale of 30 years of experience. Expert Rev Hematol 2015;8:367-74.
    • (2015) Expert Rev Hematol , vol.8 , pp. 367-374
    • Liumbruno, G.M.1    Marano, G.2    Grazzini, G.3
  • 95
    • 84876742256 scopus 로고    scopus 로고
    • A regional haemovigilance retrospective study of four types of therapeutic plasma in a ten-year survey period in France
    • Bost V, Odent-Malaure H, Chavarin P, et al. A regional haemovigilance retrospective study of four types of therapeutic plasma in a ten-year survey period in France. Vox Sang 2013;104:337-41.
    • (2013) Vox Sang , vol.104 , pp. 337-341
    • Bost, V.1    Odent-Malaure, H.2    Chavarin, P.3
  • 96
    • 0002371605 scopus 로고    scopus 로고
    • Effects of solvent/detergent-treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery
    • Haubelt H, Blome M, Kiessling AH, et al. Effects of solvent/detergent-treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang 2002;82:9-14.
    • (2002) Vox Sang , vol.82 , pp. 9-14
    • Haubelt, H.1    Blome, M.2    Kiessling, A.H.3
  • 97
    • 34547808148 scopus 로고    scopus 로고
    • Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura
    • Scully M, Longair I, Flynn M, et al. Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura. Vox Sang 2007;93:154-8.
    • (2007) Vox Sang , vol.93 , pp. 154-158
    • Scully, M.1    Longair, I.2    Flynn, M.3
  • 98
    • 20544468386 scopus 로고    scopus 로고
    • Universal fresh-frozen plasma (Uniplas): an exploratory study in adult patients undergoing elective liver resection
    • Solheim BG, Granov DA, Juravlev VA, et al. Universal fresh-frozen plasma (Uniplas): an exploratory study in adult patients undergoing elective liver resection. Vox Sang 2005;89:19-26.
    • (2005) Vox Sang , vol.89 , pp. 19-26
    • Solheim, B.G.1    Granov, D.A.2    Juravlev, V.A.3
  • 99
    • 84943739625 scopus 로고    scopus 로고
    • Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study
    • Toussaint-Hacquard M, Coppo P, Soudant M, et al. Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study. Transfusion 2015;55:2445-51.
    • (2015) Transfusion , vol.55 , pp. 2445-2451
    • Toussaint-Hacquard, M.1    Coppo, P.2    Soudant, M.3
  • 100
    • 84997419183 scopus 로고    scopus 로고
    • A single-center prospective study on the safety of plasma exchange procedures using a double-viral-inactivated and prion-reduced solvent/detergent fresh-frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy
    • Vendramin C, McGuckin S, Alwan F, et al. A single-center prospective study on the safety of plasma exchange procedures using a double-viral-inactivated and prion-reduced solvent/detergent fresh-frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy. Transfusion 2017;57:131-6.
    • (2017) Transfusion , vol.57 , pp. 131-136
    • Vendramin, C.1    McGuckin, S.2    Alwan, F.3
  • 101
    • 85011587144 scopus 로고    scopus 로고
    • Changes in hemostasis caused by different replacement fluids and outcome in therapeutic plasma exchange in pediatric patients in a retrospective single center study
    • Witt V, Pichler H, Beiglboeck E, et al. Changes in hemostasis caused by different replacement fluids and outcome in therapeutic plasma exchange in pediatric patients in a retrospective single center study. Transfus Apher Sci 2017;56:59-65.
    • (2017) Transfus Apher Sci , vol.56 , pp. 59-65
    • Witt, V.1    Pichler, H.2    Beiglboeck, E.3
  • 102
    • 0036232969 scopus 로고    scopus 로고
    • Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP)
    • de Jonge J, Groenland TH, Metselaar HJ, et al. Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP). Anesth Analg 2002;94:1127-31.
    • (2002) Anesth Analg , vol.94 , pp. 1127-1131
    • de Jonge, J.1    Groenland, T.H.2    Metselaar, H.J.3
  • 103
    • 34249717261 scopus 로고    scopus 로고
    • Fatal fibrinolysis during orthotopic liver transplantation in patients receiving solvent/detergent-treated plasma (Octaplas)
    • Magner JJ, Crowley KJ, Boylan JF. Fatal fibrinolysis during orthotopic liver transplantation in patients receiving solvent/detergent-treated plasma (Octaplas). J Cardiothorac Vasc Anesth 2007;21:410-3.
    • (2007) J Cardiothorac Vasc Anesth , vol.21 , pp. 410-413
    • Magner, J.J.1    Crowley, K.J.2    Boylan, J.F.3
  • 104
    • 33751523641 scopus 로고    scopus 로고
    • A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment
    • Heger A, Romisch J, Svae TE. A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment. Transfus Apher Sci 2006;35:223-33.
    • (2006) Transfus Apher Sci , vol.35 , pp. 223-233
    • Heger, A.1    Romisch, J.2    Svae, T.E.3
  • 105
    • 84883896424 scopus 로고    scopus 로고
    • Recovery, safety, and tolerability of a solvent/detergent-treated and prion-safeguarded transfusion plasma in a randomized, crossover, clinical trial in healthy volunteers
    • Jilma-Stohlawetz P, Kursten FW, Horvath M, et al. Recovery, safety, and tolerability of a solvent/detergent-treated and prion-safeguarded transfusion plasma in a randomized, crossover, clinical trial in healthy volunteers. Transfusion 2013;53:1906-17.
    • (2013) Transfusion , vol.53 , pp. 1906-1917
    • Jilma-Stohlawetz, P.1    Kursten, F.W.2    Horvath, M.3
  • 106
    • 84878919067 scopus 로고    scopus 로고
    • Plasma transfusion in liver transplantation: a randomized, double-blind, multicenter clinical comparison of three virally secured plasmas
    • Bartelmaos T, Chabanel A, Leger J, et al. Plasma transfusion in liver transplantation: a randomized, double-blind, multicenter clinical comparison of three virally secured plasmas. Transfusion 2013;53:1335-45.
    • (2013) Transfusion , vol.53 , pp. 1335-1345
    • Bartelmaos, T.1    Chabanel, A.2    Leger, J.3
  • 107
    • 84880298407 scopus 로고    scopus 로고
    • Solvent detergent vs. fresh frozen plasma in cirrhotic patients undergoing liver transplant surgery: a prospective randomized control study
    • Bindi ML, Miccoli M, Marietta M, et al. Solvent detergent vs. fresh frozen plasma in cirrhotic patients undergoing liver transplant surgery: a prospective randomized control study. Vox Sang 2013;105:137-43.
    • (2013) Vox Sang , vol.105 , pp. 137-143
    • Bindi, M.L.1    Miccoli, M.2    Marietta, M.3
  • 108
    • 85062687116 scopus 로고    scopus 로고
    • Resuscitation of endotheliopathy and bleeding in thoracic aortic dissections: the VIPER-OCTA randomized clinical pilot trial
    • Stensballe J, Ulrich AG, Nilsson JC, et al. Resuscitation of endotheliopathy and bleeding in thoracic aortic dissections: the VIPER-OCTA randomized clinical pilot trial. Anesth Analg 2018;127:920-7.
    • (2018) Anesth Analg , vol.127 , pp. 920-927
    • Stensballe, J.1    Ulrich, A.G.2    Nilsson, J.C.3
  • 109
    • 0242677709 scopus 로고    scopus 로고
    • Universal fresh frozen plasma (Uniplas): a safe product in open-heart surgery
    • Tølløfsrud S, Noddeland H, Svennevig JL, et al. Universal fresh frozen plasma (Uniplas): a safe product in open-heart surgery. Intensive Care Med 2003;29:1736-43.
    • (2003) Intensive Care Med , vol.29 , pp. 1736-1743
    • Tølløfsrud, S.1    Noddeland, H.2    Svennevig, J.L.3
  • 110
    • 0032740602 scopus 로고    scopus 로고
    • A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation
    • Williamson LM, Llewelyn CA, Fisher NC, et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 1999;39:1227-34.
    • (1999) Transfusion , vol.39 , pp. 1227-1234
    • Williamson, L.M.1    Llewelyn, C.A.2    Fisher, N.C.3
  • 111
    • 0037206589 scopus 로고    scopus 로고
    • Universal solvent/detergent-treated fresh frozen plasma (Uniplas--rationale and clinical properties)
    • Noddeland H, Tollofsrud S, Svennevig J, et al. Universal solvent/detergent-treated fresh frozen plasma (Uniplas--rationale and clinical properties). Thromb Res 2002;107(Suppl 1):S33-7.
    • (2002) Thromb Res , vol.107 , pp. S33-S37
    • Noddeland, H.1    Tollofsrud, S.2    Svennevig, J.3
  • 112
    • 0034995507 scopus 로고    scopus 로고
    • Developing guidance for budget impact analysis
    • Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics 2001;19:609-21.
    • (2001) Pharmacoeconomics , vol.19 , pp. 609-621
    • Trueman, P.1    Drummond, M.2    Hutton, J.3
  • 113
    • 56849128234 scopus 로고    scopus 로고
    • Cost-effectiveness analysis: what it really means for transfusion medicine decision making
    • Custer B, Hoch JS. Cost-effectiveness analysis: what it really means for transfusion medicine decision making. Transfus Med Rev 2009;23:1-12.
    • (2009) Transfus Med Rev , vol.23 , pp. 1-12
    • Custer, B.1    Hoch, J.S.2
  • 114
    • 85066823630 scopus 로고    scopus 로고
    • Health economics and blood safety
    • Shan H, Dodd RY, , editors., New York, Springer International Publishing, p
    • Custer B. Health economics and blood safety. In: Shan H Dodd RY, editors. Blood Safety: A Guide to Monitoring and Responding to Potential New Threats. New York: Springer International Publishing; 2019. p. 53-81.
    • (2019) Blood Safety: A Guide to Monitoring and Responding to Potential New Threats , pp. 53-81
    • Custer, B.1
  • 115
    • 84930481789 scopus 로고    scopus 로고
    • Highlights of PBTI Coimbra Conference on PRT of plasma & current opinions on pathogen reduction treatment of blood components
    • de Sousa G, Seghatchian J. Highlights of PBTI Coimbra Conference on PRT of plasma & current opinions on pathogen reduction treatment of blood components. Transfus Apher Sci 2015;52:228-32.
    • (2015) Transfus Apher Sci , vol.52 , pp. 228-232
    • de Sousa, G.1    Seghatchian, J.2
  • 116
    • 84880703877 scopus 로고    scopus 로고
    • Update on the use of pathogen-reduced human plasma and platelet concentrates
    • Seltsam A, Muller TH. Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol 2013;162:442-54.
    • (2013) Br J Haematol , vol.162 , pp. 442-454
    • Seltsam, A.1    Muller, T.H.2
  • 117
    • 84875585172 scopus 로고    scopus 로고
    • Component pathogen inactivation: a critical review
    • Prowse CV. Component pathogen inactivation: a critical review. Vox Sang 2013;104:183-99.
    • (2013) Vox Sang , vol.104 , pp. 183-199
    • Prowse, C.V.1
  • 118
    • 85020513631 scopus 로고    scopus 로고
    • Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?
    • Di Minno G, Navarro D, Perno CF, et al. Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients? Ann Hematol 2017;96:1253-70.
    • (2017) Ann Hematol , vol.96 , pp. 1253-1270
    • Di Minno, G.1    Navarro, D.2    Perno, C.F.3
  • 119
    • 85021819922 scopus 로고    scopus 로고
    • Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology
    • Yonemura S, Doane S, Keil S, et al. Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology. Blood Transfus 2017;15:357-64.
    • (2017) Blood Transfus , vol.15 , pp. 357-364
    • Yonemura, S.1    Doane, S.2    Keil, S.3
  • 120
    • 85013498005 scopus 로고    scopus 로고
    • Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study
    • Cancelas JA, Gottschall JL, Rugg N, et al. Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study. Vox Sang 2017;112:210-8.
    • (2017) Vox Sang , vol.112 , pp. 210-218
    • Cancelas, J.A.1    Gottschall, J.L.2    Rugg, N.3
  • 121
    • 85031943518 scopus 로고    scopus 로고
    • Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries
    • Drew VJ, Barro L, Seghatchian J, et al. Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries. Blood Transfus 2017;15:512-21.
    • (2017) Blood Transfus , vol.15 , pp. 512-521
    • Drew, V.J.1    Barro, L.2    Seghatchian, J.3
  • 122
    • 84978499751 scopus 로고    scopus 로고
    • Quality of red cells after combination of prion reduction and treatment with the intercept system for pathogen inactivation
    • Wiltshire M, Meli A, Schott MA, et al. Quality of red cells after combination of prion reduction and treatment with the intercept system for pathogen inactivation. Transfus Med 2016;26:208-14.
    • (2016) Transfus Med , vol.26 , pp. 208-214
    • Wiltshire, M.1    Meli, A.2    Schott, M.A.3
  • 123
    • 84964413510 scopus 로고    scopus 로고
    • Effect of plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial
    • Allain JP, Owusu-Ofori AK, Assennato SM, et al. Effect of plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial. Lancet 2016;387:1753-61.
    • (2016) Lancet , vol.387 , pp. 1753-1761
    • Allain, J.P.1    Owusu-Ofori, A.K.2    Assennato, S.M.3
  • 125
    • 85056068335 scopus 로고    scopus 로고
    • Budget impact of implementing platelet pathogen reduction into the Italian blood transfusion system
    • Cicchetti A, Coretti S, Sacco F, et al. Budget impact of implementing platelet pathogen reduction into the Italian blood transfusion system. Blood Transfus 2018;16:483-9.
    • (2018) Blood Transfus , vol.16 , pp. 483-489
    • Cicchetti, A.1    Coretti, S.2    Sacco, F.3
  • 126
    • 84891872378 scopus 로고    scopus 로고
    • Reducing the financial impact of pathogen inactivation technology for platelet components: our experience
    • Girona-Llobera E, Jimenez-Marco T, Galmes-Trueba A, et al. Reducing the financial impact of pathogen inactivation technology for platelet components: our experience. Transfusion 2014;54:158-68.
    • (2014) Transfusion , vol.54 , pp. 158-168
    • Girona-Llobera, E.1    Jimenez-Marco, T.2    Galmes-Trueba, A.3
  • 127
    • 84959489610 scopus 로고    scopus 로고
    • Blood-Borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium
    • Walsh GM, Shih AW, Solh Z, et al. Blood-Borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium. Transfus Med Rev 2016;30:53-68.
    • (2016) Transfus Med Rev , vol.30 , pp. 53-68
    • Walsh, G.M.1    Shih, A.W.2    Solh, Z.3
  • 128
    • 85044344779 scopus 로고    scopus 로고
    • Efforts toward elimination of infectious agents in blood products
    • Jacquot C, Delaney M. Efforts toward elimination of infectious agents in blood products. J Intensive Care Med 2018;33:543-50.
    • (2018) J Intensive Care Med , vol.33 , pp. 543-550
    • Jacquot, C.1    Delaney, M.2
  • 129
    • 70449092374 scopus 로고    scopus 로고
    • Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies
    • Picker SM, Schneider V, Oustianskaia L, et al. Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies. Transfusion 2009;49:2311-8.
    • (2009) Transfusion , vol.49 , pp. 2311-2318
    • Picker, S.M.1    Schneider, V.2    Oustianskaia, L.3
  • 130
    • 85050123261 scopus 로고    scopus 로고
    • Ultraviolet-based pathogen inactivation systems: untangling the molecular targets activated in platelets
    • Schubert P, Johnson L, Marks DC, et al. Ultraviolet-based pathogen inactivation systems: untangling the molecular targets activated in platelets. Front Med (Lausanne) 2018;5:129.
    • (2018) Front Med (Lausanne) , vol.5 , pp. 129
    • Schubert, P.1    Johnson, L.2    Marks, D.C.3
  • 131
    • 78651284022 scopus 로고    scopus 로고
    • A comparison of methods of pathogen inactivation of FFP
    • Rock G. A comparison of methods of pathogen inactivation of FFP. Vox Sang 2011;100:169-78.
    • (2011) Vox Sang , vol.100 , pp. 169-178
    • Rock, G.1
  • 132
    • 85026448014 scopus 로고    scopus 로고
    • Pathogen-reduced platelets for the prevention of bleeding
    • Butler C, Doree C, Estcourt LJ, et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev 2013;3:CD009072.
    • (2013) Cochrane Database Syst Rev , vol.3 , pp. CD009072
    • Butler, C.1    Doree, C.2    Estcourt, L.J.3
  • 133
  • 134
    • 40749148572 scopus 로고    scopus 로고
    • Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation
    • Reddy HL, Dayan AD, Cavagnaro J, et al. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev 2008;22:133-53.
    • (2008) Transfus Med Rev , vol.22 , pp. 133-153
    • Reddy, H.L.1    Dayan, A.D.2    Cavagnaro, J.3
  • 135
    • 79851490196 scopus 로고    scopus 로고
    • Development of the S-303 pathogen inactivation technology for red blood cell concentrates
    • Henschler R, Seifried E, Mufti N. Development of the S-303 pathogen inactivation technology for red blood cell concentrates. Transfus Med Hemother 2011;38:33-42.
    • (2011) Transfus Med Hemother , vol.38 , pp. 33-42
    • Henschler, R.1    Seifried, E.2    Mufti, N.3
  • 136
    • 85016240547 scopus 로고    scopus 로고
    • Whole blood pathogen reduction technology and blood safety in sub-Saharan Africa: a systematic review with regional discussion
    • Nkohkwo A, Agbor G, Asongalem E, et al. Whole blood pathogen reduction technology and blood safety in sub-Saharan Africa: a systematic review with regional discussion. Afr J Lab Med 2016;5:363.
    • (2016) Afr J Lab Med , vol.5 , pp. 363
    • Nkohkwo, A.1    Agbor, G.2    Asongalem, E.3
  • 137
    • 84937435830 scopus 로고    scopus 로고
    • Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections
    • Stramer SL. Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections. ISBT Sci Ser 2014;9:30-6.
    • (2014) ISBT Sci Ser , vol.9 , pp. 30-36
    • Stramer, S.L.1
  • 138
    • 85053126632 scopus 로고    scopus 로고
    • Reflections on the dynamics of bacterial and viral contamination of blood components and the levels of efficacy for pathogen inactivation processes
    • Bah A, Cardoso M, Seghatchian J, et al. Reflections on the dynamics of bacterial and viral contamination of blood components and the levels of efficacy for pathogen inactivation processes. Transfus Apher Sci 2018;57:683-8. https://doi.org/10.1016/j.transci.2018.09.004.
    • (2018) Transfus Apher Sci , vol.57 , pp. 683-688
    • Bah, A.1    Cardoso, M.2    Seghatchian, J.3
  • 139
    • 85059281051 scopus 로고    scopus 로고
    • Interpretation of pathogen load in relationship to infectivity and pathogen reduction efficacy
    • McCullough J, Alter HJ, Ness PM. Interpretation of pathogen load in relationship to infectivity and pathogen reduction efficacy. Transfusion 2018;59:1132-46. https://doi.org/10.1111/trf.15103.
    • (2018) Transfusion , vol.59 , pp. 1132-1146
    • McCullough, J.1    Alter, H.J.2    Ness, P.M.3
  • 140
    • 84897020686 scopus 로고    scopus 로고
    • Hepatitis E transmission by transfusion of intercept blood system-treated plasma
    • Hauser L1, Roque-Afonso AM, Beylouné A, et al. Hepatitis E transmission by transfusion of intercept blood system-treated plasma. Blood 2014;123:796-7.
    • (2014) Blood , vol.123 , pp. 796-797
    • Hauser, L.1.1    Roque-Afonso, A.M.2    Beylouné, A.3
  • 141
    • 85066860948 scopus 로고    scopus 로고
    • Mirasol Evaluation of Reduction in Infections Trial (MERIT) [Internet]. Identifier NCT03737669. Bethesda (MD) National Library of Medicine; 2018. Available from, https://clinicaltrials.gov/ct2/show/NCT03737669
    • Mirasol Evaluation of Reduction in Infections Trial (MERIT). ClinicalTrials.gov. Mirasol Evaluation of Reduction in Infections Trial (MERIT) [Internet]. Identifier NCT03737669. Bethesda (MD): National Library of Medicine; 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT03737669.
  • 142
    • 84878113969 scopus 로고    scopus 로고
    • Analysis of reasons for not implementing pathogen inactivation for platelet concentrates
    • Lozano M, Cid J. Analysis of reasons for not implementing pathogen inactivation for platelet concentrates. Transfus Clin Biol 2013;20:158-64.
    • (2013) Transfus Clin Biol , vol.20 , pp. 158-164
    • Lozano, M.1    Cid, J.2
  • 143
    • 85047087677 scopus 로고    scopus 로고
    • Special considerations for the use of pathogen reduced blood components in pediatric patients: an overview
    • Goodrich RP, Segatchian J. Special considerations for the use of pathogen reduced blood components in pediatric patients: an overview. Transfus Apher Sci 2018;57:374-7.
    • (2018) Transfus Apher Sci , vol.57 , pp. 374-377
    • Goodrich, R.P.1    Segatchian, J.2
  • 144
    • 85066847522 scopus 로고    scopus 로고
    • Available from
    • JICA Hands over Blood Safety Technology Project to National Blood Service. National Blood Service Ghana. [cited 2018 Sep 17]. Available from: https://nbsghana.org/jica-hands-over-blood-safety-technology-project-to-national-blood-service/.
    • National Blood Service Ghana. [cited 2018 Sep 17]
  • 145
    • 84904501752 scopus 로고    scopus 로고
    • Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment
    • Winter KM, Johnson L, Kwok M, et al. Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment. Transfusion 2014;54:1798-807.
    • (2014) Transfusion , vol.54 , pp. 1798-1807
    • Winter, K.M.1    Johnson, L.2    Kwok, M.3
  • 146
    • 80054746871 scopus 로고    scopus 로고
    • Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment
    • North A, Ciaravino V, Mufti N, et al. Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment. Transfusion 2011;51:2208-18.
    • (2011) Transfusion , vol.51 , pp. 2208-2218
    • North, A.1    Ciaravino, V.2    Mufti, N.3
  • 147
    • 77649191792 scopus 로고    scopus 로고
    • Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC
    • Mufti NA, Erickson AC, North AK, et al. Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals 2010;38:14-9.
    • (2010) Biologicals , vol.38 , pp. 14-19
    • Mufti, N.A.1    Erickson, A.C.2    North, A.K.3
  • 148
    • 79960186991 scopus 로고    scopus 로고
    • Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process
    • Cancelas JA, Dumont LJ, Rugg N, et al. Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process. Transfusion 2011;51:2367-76.
    • (2011) Transfusion , vol.51 , pp. 2367-2376
    • Cancelas, J.A.1    Dumont, L.J.2    Rugg, N.3
  • 149
    • 85042607509 scopus 로고    scopus 로고
    • Red blood cells treated with the amustaline (S-303) pathogen reduction system: a transfusion study in cardiac surgery
    • Brixner V, Kiessling AH, Madlener K, et al. Red blood cells treated with the amustaline (S-303) pathogen reduction system: a transfusion study in cardiac surgery. Transfusion 2018;58:905-16.
    • (2018) Transfusion , vol.58 , pp. 905-916
    • Brixner, V.1    Kiessling, A.H.2    Madlener, K.3
  • 152
    • 85061771264 scopus 로고    scopus 로고
    • The pathogen-reduced red blood cell suspension: single centre study of clinical safety and efficacy in children with oncological and haematological diseases
    • Trakhtman P, Kumukova I, Starostin N, et al. The pathogen-reduced red blood cell suspension: single centre study of clinical safety and efficacy in children with oncological and haematological diseases. Vox Sang 2019;114:223-31.
    • (2019) Vox Sang , vol.114 , pp. 223-231
    • Trakhtman, P.1    Kumukova, I.2    Starostin, N.3
  • 153
    • 4644239596 scopus 로고    scopus 로고
    • Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level
    • Kumar V, Lockerbie O, Keil SD, et al. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004;80:15-21.
    • (2004) Photochem Photobiol , vol.80 , pp. 15-21
    • Kumar, V.1    Lockerbie, O.2    Keil, S.D.3
  • 154
    • 79851470298 scopus 로고    scopus 로고
    • Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light
    • Marschner S, Goodrich R. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011;38:8-18.
    • (2011) Transfus Med Hemother , vol.38 , pp. 8-18
    • Marschner, S.1    Goodrich, R.2
  • 155
    • 85017742830 scopus 로고    scopus 로고
    • Red cells from riboflavin plus UV-light treated whole blood can be effectively radiolabeled with 51-Cr for viabiliity studies
    • Cancelas JA, Rugg N, Pratt PG, et al. Red cells from riboflavin plus UV-light treated whole blood can be effectively radiolabeled with 51-Cr for viabiliity studies. Transfusion 2009;49(S3):108A (S44).
    • (2009) Transfusion , vol.49 , Issue.S3 , pp. 108A S44
    • Cancelas, J.A.1    Rugg, N.2    Pratt, P.G.3
  • 156
    • 79960172472 scopus 로고    scopus 로고
    • In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood
    • Cancelas JA, Rugg N, Fletcher D, et al. In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood. Transfusion 2011;51:1460-8.
    • (2011) Transfusion , vol.51 , pp. 1460-1468
    • Cancelas, J.A.1    Rugg, N.2    Fletcher, D.3
  • 157
    • 84855854717 scopus 로고    scopus 로고
    • Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood
    • Tonnetti L, Thorp AM, Reddy HL, et al. Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood. Transfusion 2012;52:409-16.
    • (2012) Transfusion , vol.52 , pp. 409-416
    • Tonnetti, L.1    Thorp, A.M.2    Reddy, H.L.3
  • 158
    • 84890429898 scopus 로고    scopus 로고
    • Inactivation of Plasmodium falciparum in whole blood by riboflavin plus irradiation
    • El Chaar M, Atwal S, Freimanis GL, et al. Inactivation of Plasmodium falciparum in whole blood by riboflavin plus irradiation. Transfusion 2013;53:3174-83.
    • (2013) Transfusion , vol.53 , pp. 3174-3183
    • El Chaar, M.1    Atwal, S.2    Freimanis, G.L.3
  • 159
    • 84873460097 scopus 로고    scopus 로고
    • Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease?
    • Fast LD, Nevola M, Tavares J, et al. Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease? Transfusion 2013;53:373-81.
    • (2013) Transfusion , vol.53 , pp. 373-381
    • Fast, L.D.1    Nevola, M.2    Tavares, J.3
  • 160
    • 84874794455 scopus 로고    scopus 로고
    • Development of a riboflavin and ultraviolet light-based device to treat whole blood
    • Reddy HL, Doane SK, Keil SD, et al. Development of a riboflavin and ultraviolet light-based device to treat whole blood. Transfusion 2013;53(Suppl 1):131S-6S.
    • (2013) Transfusion , vol.53 , pp. 131S-6S
    • Reddy, H.L.1    Doane, S.K.2    Keil, S.D.3
  • 161
    • 84876146438 scopus 로고    scopus 로고
    • Riboflavin and ultraviolet light reduce the infectivity of Babesia microti in whole blood
    • Tonnetti L, Thorp AM, Reddy HL, et al. Riboflavin and ultraviolet light reduce the infectivity of Babesia microti in whole blood. Transfusion 2013;53:860-7.
    • (2013) Transfusion , vol.53 , pp. 860-867
    • Tonnetti, L.1    Thorp, A.M.2    Reddy, H.L.3
  • 162
    • 84924603324 scopus 로고    scopus 로고
    • Large animal evaluation of riboflavin and ultraviolet light-treated whole blood transfusion in a diffuse, nonsurgical bleeding porcine model
    • Okoye OT, Reddy H, Wong MD, et al. Large animal evaluation of riboflavin and ultraviolet light-treated whole blood transfusion in a diffuse, nonsurgical bleeding porcine model. Transfusion 2015;55:532-43.
    • (2015) Transfusion , vol.55 , pp. 532-543
    • Okoye, O.T.1    Reddy, H.2    Wong, M.D.3
  • 163
    • 84912141075 scopus 로고    scopus 로고
    • Treatment of whole blood with riboflavin and UV light: impact on malaria parasite viability and whole blood storage
    • Owusu-Ofori S, Kusi J, Owusu-Ofori A, et al. Treatment of whole blood with riboflavin and UV light: impact on malaria parasite viability and whole blood storage. Shock 2015;44(Suppl 1):33-8.
    • (2015) Shock , vol.44 , pp. 33-38
    • Owusu-Ofori, S.1    Kusi, J.2    Owusu-Ofori, A.3
  • 164
    • 84923040014 scopus 로고    scopus 로고
    • Reduction of Leishmania donovani infectivity in whole blood using riboflavin and ultraviolet light
    • Tonnetti L, Thorp AM, Reddy HL, et al. Reduction of Leishmania donovani infectivity in whole blood using riboflavin and ultraviolet light. Transfusion 2015;55:326-9.
    • (2015) Transfusion , vol.55 , pp. 326-329
    • Tonnetti, L.1    Thorp, A.M.2    Reddy, H.L.3
  • 165
    • 85017346266 scopus 로고    scopus 로고
    • Red blood cells derived from whole blood treated with riboflavin and ultraviolet light maintain adequate survival in vivo after 21 days of storage
    • Cancelas JA, Slichter SJ, Rugg N, et al. Red blood cells derived from whole blood treated with riboflavin and ultraviolet light maintain adequate survival in vivo after 21 days of storage. Transfusion 2017;57:1218-25.
    • (2017) Transfusion , vol.57 , pp. 1218-1225
    • Cancelas, J.A.1    Slichter, S.J.2    Rugg, N.3
  • 166
    • 0034912287 scopus 로고    scopus 로고
    • Inactivation of infectious pathogens in labile blood components: meeting the challenge
    • Corash L. Inactivation of infectious pathogens in labile blood components: meeting the challenge. Transfus Clin Biol 2001;8:138-45.
    • (2001) Transfus Clin Biol , vol.8 , pp. 138-145
    • Corash, L.1
  • 167
    • 78650315329 scopus 로고    scopus 로고
    • Helinx technology inactivates pathogens of emerging importance in red blood cell concentrates
    • Dupuis K, Bernard K, Jones S, et al. Helinx technology inactivates pathogens of emerging importance in red blood cell concentrates. Blood 2003;102(Suppl. 1):816a.
    • (2003) Blood , vol.102 , pp. 816a
    • Dupuis, K.1    Bernard, K.2    Jones, S.3
  • 168
    • 85066848678 scopus 로고    scopus 로고
    • High titer leukocyte inactivation in INTERCEPT red blood cells (RBC)
    • Hanson D, Propst M, Dupuis K. High titer leukocyte inactivation in INTERCEPT red blood cells (RBC). Vox Sang 2001;101a:81.
    • (2001) Vox Sang , vol.101a , pp. 81
    • Hanson, D.1    Propst, M.2    Dupuis, K.3
  • 169
    • 80055013206 scopus 로고    scopus 로고
    • Inactivation of XMRV in platelet and RBC components prepared with the INTERCEPT blood system
    • Mikovits JA, Hagen K, Liu W, et al. Inactivation of XMRV in platelet and RBC components prepared with the INTERCEPT blood system. Rev Antivir Ther Infect Dis 2010;8:36.
    • (2010) Rev Antivir Ther Infect Dis , vol.8 , pp. 36
    • Mikovits, J.A.1    Hagen, K.2    Liu, W.3
  • 170
    • 0023992260 scopus 로고
    • A new biological target of fucomarians: photochemical formation of covalent adducts with unsaturated fatty acids
    • Specht KG, Kittler L, Midden WR. A new biological target of fucomarians: photochemical formation of covalent adducts with unsaturated fatty acids. Photochem Photobiol 1988;47:537-41.
    • (1988) Photochem Photobiol , vol.47 , pp. 537-541
    • Specht, K.G.1    Kittler, L.2    Midden, W.R.3
  • 171
    • 33644848731 scopus 로고    scopus 로고
    • Thiazole orange, a DNA binding photochemical with flexible structure, can inactivate pathogens in red cell suspensions while maintaining red cell storage properties
    • Skripchenko A, Wagner SJ, Thompson-Montgomery D, et al. Thiazole orange, a DNA binding photochemical with flexible structure, can inactivate pathogens in red cell suspensions while maintaining red cell storage properties. Transfusion 2006;46:213-9.
    • (2006) Transfusion , vol.46 , pp. 213-219
    • Skripchenko, A.1    Wagner, S.J.2    Thompson-Montgomery, D.3
  • 172
    • 52049103376 scopus 로고    scopus 로고
    • Inactivation of Leishmania donavani infantum and Trypanosoma cruzi in red cell suspensions by thiazole orange
    • Wagner SJ, Skripchenko A, Salata J, et al. Inactivation of Leishmania donavani infantum and Trypanosoma cruzi in red cell suspensions by thiazole orange. Transfusion 2008;48:1363-7.
    • (2008) Transfusion , vol.48 , pp. 1363-1367
    • Wagner, S.J.1    Skripchenko, A.2    Salata, J.3
  • 173
    • 84874067331 scopus 로고    scopus 로고
    • Blue light rescues mice from potentially fatal Pseudomonas aeruginosa burn infection: efficacy, safety, and mechanism of action
    • Dai T, Gupta A, Huang YY, et al. Blue light rescues mice from potentially fatal Pseudomonas aeruginosa burn infection: efficacy, safety, and mechanism of action. Antimicrob Agents Chemother 2013;57:1238-45.
    • (2013) Antimicrob Agents Chemother , vol.57 , pp. 1238-1245
    • Dai, T.1    Gupta, A.2    Huang, Y.Y.3
  • 174
    • 84906048093 scopus 로고    scopus 로고
    • 405 nm light technology for the inactivation of pathogens and its potential role for environmental disinfection and infection control
    • Maclean M, McKenzie K, Anderson JG, et al. 405 nm light technology for the inactivation of pathogens and its potential role for environmental disinfection and infection control. J Hosp Infect 2014;88:1-11.
    • (2014) J Hosp Infect , vol.88 , pp. 1-11
    • Maclean, M.1    McKenzie, K.2    Anderson, J.G.3
  • 175
    • 85032853700 scopus 로고    scopus 로고
    • A new proof-of-concept in bacterial reduction: antimicrobial action of violet-blue light (405 nm) in ex vivo stored plasma
    • Maclean M, White T, Anderson JG, et al. A new proof-of-concept in bacterial reduction: antimicrobial action of violet-blue light (405 nm) in ex vivo stored plasma. J Blood Transfus 2016;2016:2920514.
    • (2016) J Blood Transfus , vol.2016 , pp. 2920514
    • Maclean, M.1    White, T.2    Anderson, J.G.3
  • 176
    • 63849253384 scopus 로고    scopus 로고
    • Inactivation of bacterial pathogens following exposure to light from a 405-nm LED array
    • Maclean M, MacGregor SJ, Anderson JG, et al. Inactivation of bacterial pathogens following exposure to light from a 405-nm LED array. Appl Environ Microbiol 2009;75:1932-7.
    • (2009) Appl Environ Microbiol , vol.75 , pp. 1932-1937
    • Maclean, M.1    MacGregor, S.J.2    Anderson, J.G.3
  • 177
    • 85007490527 scopus 로고    scopus 로고
    • Investigating the influence of biologically-relevant suspending media on 405 nm light inactivation of feline calicivirus: a surrogate of norovirus
    • Tomb RM, Maclean M, JE Coia E, et al. Investigating the influence of biologically-relevant suspending media on 405 nm light inactivation of feline calicivirus: a surrogate of norovirus. Food Environ Virol 2017;9:159-67.
    • (2017) Food Environ Virol , vol.9 , pp. 159-167
    • Tomb, R.M.1    Maclean, M.2    JE Coia, E.3
  • 178
    • 84961789585 scopus 로고    scopus 로고
    • US Army blood program: 2025 and beyond
    • Gonzales R, Taylor AL, Atkinson AJ, et al. US Army blood program: 2025 and beyond. Transfusion 2016;56(Suppl 1):S85-93.
    • (2016) Transfusion , vol.56 , pp. S85-93
    • Gonzales, R.1    Taylor, A.L.2    Atkinson, A.J.3
  • 179
    • 85060543482 scopus 로고    scopus 로고
    • Cold-stored platelets: A product with function optimized for hemorrhage control
    • Reddoch-Cardenas KM, Bynum JA, Meledeo MA, et al. Cold-stored platelets: A product with function optimized for hemorrhage control. Transfus Apher Sci 2019;58:16-22.
    • (2019) Transfus Apher Sci , vol.58 , pp. 16-22
    • Reddoch-Cardenas, K.M.1    Bynum, J.A.2    Meledeo, M.A.3
  • 180
    • 0037428090 scopus 로고    scopus 로고
    • The clearance mechanism of chilled blood platelets
    • Hoffmeister KM, Felbinger TW, Falet H, et al. The clearance mechanism of chilled blood platelets. Cell 2003;112:87-97.
    • (2003) Cell , vol.112 , pp. 87-97
    • Hoffmeister, K.M.1    Felbinger, T.W.2    Falet, H.3
  • 181
    • 85040778532 scopus 로고    scopus 로고
    • Transfusion with cold stored platelets in patients undergoing complex cardiothoracic surgery with cardiopulmonary bypass circulation: effect on bleeding and thromboembolic risk
    • Apelseth TO, Kristoffersen EK, Kvalheim VL, et al. Transfusion with cold stored platelets in patients undergoing complex cardiothoracic surgery with cardiopulmonary bypass circulation: effect on bleeding and thromboembolic risk. Transfusion 2017;57:3A-4A.
    • (2017) Transfusion , vol.57 , pp. 3A-4A
    • Apelseth, T.O.1    Kristoffersen, E.K.2    Kvalheim, V.L.3
  • 182
    • 85057869101 scopus 로고    scopus 로고
    • The impact of refrigerated storage of UVC pathogen inactivated platelet concentrates on in vitro platelet quality parameters
    • Johnson L, Cameron M, Waters L, et al. The impact of refrigerated storage of UVC pathogen inactivated platelet concentrates on in vitro platelet quality parameters. Vox Sang 2019;114:47-56.
    • (2019) Vox Sang , vol.114 , pp. 47-56
    • Johnson, L.1    Cameron, M.2    Waters, L.3
  • 183
    • 85048143148 scopus 로고    scopus 로고
    • Refrigeration, cryopreservation and pathogen inactivation: an updated perspective on platelet storage conditions
    • Waters L, Cameron M, Padula MP, et al. Refrigeration, cryopreservation and pathogen inactivation: an updated perspective on platelet storage conditions. Vox Sang 2018;113:317-28.
    • (2018) Vox Sang , vol.113 , pp. 317-328
    • Waters, L.1    Cameron, M.2    Padula, M.P.3
  • 184
    • 84872232512 scopus 로고    scopus 로고
    • Primary hemostatic capacity of whole blood: a comprehensive analysis of pathogen reduction and refrigeration effects over time
    • Pidcoke HF, McFaul SJ, Ramasubramanian AK, et al. Primary hemostatic capacity of whole blood: a comprehensive analysis of pathogen reduction and refrigeration effects over time. Transfusion 2013;53(Suppl 1):137S-49S.
    • (2013) Transfusion , vol.53 , pp. 137S-49S
    • Pidcoke, H.F.1    McFaul, S.J.2    Ramasubramanian, A.K.3
  • 185
    • 85073836758 scopus 로고    scopus 로고
    • Hemostatic functional preservation of refrigerated whole blood over 35 days
    • Meledeo MA, Peltier GC, McIntosh CS, et al. Hemostatic functional preservation of refrigerated whole blood over 35 days. Transfusion 2018;58:62A.
    • (2018) Transfusion , vol.58 , pp. 62A
    • Meledeo, M.A.1    Peltier, G.C.2    McIntosh, C.S.3
  • 186
    • 79955852870 scopus 로고    scopus 로고
    • Lyophilized platelets: challenges and opportunities
    • Cap AP, Perkins JG. Lyophilized platelets: challenges and opportunities. J Trauma 2011;70(5 Suppl):S59-60.
    • (2011) J Trauma , vol.70 , Issue.5 , pp. S59-60
    • Cap, A.P.1    Perkins, J.G.2
  • 187
    • 84961807639 scopus 로고    scopus 로고
    • Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro
    • Cap AP, Pidcoke HF, Keil SD, et al. Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro. Transfusion 2016;56(Suppl 1):S6-15.
    • (2016) Transfusion , vol.56 , pp. S6-15
    • Cap, A.P.1    Pidcoke, H.F.2    Keil, S.D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.